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Summary
BACKGROUND/AIMS: Switzerland’s drug policy model
has always been unique and progressive, but there is a need
to reassess this system in a rapidly changing world. The
IMPROVE study was conducted to gain understanding of
the attitudes and beliefs towards opioid maintenance ther-
apy (OMT) in Switzerland with regards to quality and ac-
cess to treatment. To obtain a “real-world” view on OMT,
the study approached its goals from two different angles:
from the perspectives of the OMT patients and of the phys-
icians who treat patients with maintenance therapy. The
IMPROVE study collected a large body of data on OMT in
Switzerland. This paper presents a small subset of the data-
set, focusing on the research design and methodology, the
profile of the participants and the responses to several key
questions addressed by the questionnaires.
METHODS: IMPROVE was an observational,
questionnaire-based cross-sectional study on OMT conduc-
ted in Switzerland. Respondents consisted of OMT pa-
tients and treating physicians from various regions of the
country. Data were collected using questionnaires in Ger-
man and French. Physicians were interviewed by phone
with a computer-based questionnaire. Patients self-com-
pleted a paper-based questionnaire at the physicians’ of-
fices or OMT treatment centres.
RESULTS: A total of 200 physicians and 207 patients par-
ticipated in the study. Liquid methadone and methadone
tablets or capsules were the medications most commonly
prescribed by physicians (60% and 20% of patient load, re-
spectively) whereas buprenorphine use was less frequent.
Patients (88%) and physicians (83%) were generally satis-
fied with the OMT currently offered. The current political
framework and lack of training or information were cited
as determining factors that deter physicians from engaging
in OMT. About 31% of OMT physicians interviewed were
≥60 years old, indicating an ageing population. Diversion
and misuse were considered a significant problem in
Switzerland by 45% of the physicians.
CONCLUSION: The subset of IMPROVE data presented
gives a present-day, real-life overview of the OMT land-
scape in Switzerland. It represents a valuable resource for
policy makers, key opinion leaders and drug addiction re-
searchers and will be a useful basis for improving the cur-
rent Swiss OMT model.
Key words: opioid maintenance therapy (OMT);
methadone; buprenorphine; Switzerland; survey;
IMPROVE study
Introduction
As estimated 25 million people worldwide are drug-de-
pendent and a large majority of these (approximately 15.6
million) are illicit opioid users. Opioid dependence is a re-
cognised chronic relapsing condition associated with high
economic burden, not only in terms of direct healthcare
costs, but also expenditures in social welfare, productivity
loss, depression and law enforcement [1].
Switzerland’s drug policy model has always been unique
and progressive and is based on “four pillars”, consisting
of measures in the following four areas: prevention, ther-
apy, harm reduction and law enforcement [2]. The first
European supervised drug-consumption room was estab-
lished in Bern in 1986. In the years that followed, more of
these facilities were established all over the country, which
gave status to medical institutions in Switzerland [3]. A
great deal of the evidence base on opioid substitution treat-
ment was collected from these settings [4–7].
A recent United Nations survey reported that about 0.6% of
the Swiss population aged 15 to 64 years are opioid users
[8]. Of the estimated 22,000 opioid-dependent individuals
in Switzerland, more than 85% are in therapy [9]. Cur-
rent clinical guidelines from the Swiss Society of Addic-
tion Medicine (SSAM), the Swiss Association of the Med-
ical Officers of the Cantons (VKS), and the Federal Office
of Public Health (FOPH) fully support opioid mainten-
ance therapy (OMT), with methadone and buprenorphine
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as the recommended first-line OMT medications [10].
Substitution-assisted treatment is covered by the Swiss ob-
ligatory health insurance system, but with certain limita-
tions. Take-home medications on weekends and holidays
are generally allowed, albeit with restrictions.
However, although the Swiss model at first glance seems
to work smoothly, there is a need to reassess this system in
a rapidly changing world. Over the years, new legislations,
treatment options and drug-related problems have arisen.
Regional differences across the country still abound.
In addition, the main players in OMT are changing. The
demographics of the drug scene have been transformed as
the drug addicts of the 1980s have aged and a new gen-
eration of drug users is emerging [6, 10]. In parallel, the
profile of the treating physician may also be changing as
the OMT pioneers of 30 years ago go into retirement and a
younger generation of doctors take over treatment respons-
ibilities.
It is important, now more than ever, to determine the “real-
world” perspectives on OMT to help optimise decision
making regarding treatment provisions.
The IMPROVE study aimed to gain understanding of the
attitudes and beliefs towards OMT in Switzerland with re-
gards to quality and access to treatment. To obtain a “real-
world” view of OMT, the study approached its goals from
two different angles, from the perspectives of the OMT pa-
tients and of the treating physicians.
The IMPROVE study collected a large body of data on
OMT in Switzerland. This paper presents an overview of
the IMPROVE study using a small subset of the dataset, fo-
cusing on the research design and methodology, as well as
the demographic profile of the participants. In addition, the
responses to several key questions are presented, includ-
ing medication choices, therapy satisfaction, diversion and
misuse. Other important data will be presented in subse-
quent publications.
Subjects and methods
Design and recruitment
IMPROVE was an observational, questionnaire-based,
cross-sectional study on OMT conducted in Switzerland.
Respondents consisted of OMT patients and treating physi-
cians from various regions of the country. Recruitment was
implemented through the Swiss drug treatment centres that
offer help and support to patients and drug users, as well as
through physicians who are active in the field of drug sub-
stitution research and practice.
The recruitment centres were selected on the basis of the
size of the canton where the centre is located, the size and
importance of the centre and membership of OMT-relevant
networks (e.g., SSAM). On the basis of these considera-
tions, sites from the biggest cities in Switzerland were iden-
tified. For political reasons, the city of Geneva could not be
included, but other parts of French-speaking Switzerland
were covered. Lugano was excluded for logistical reasons;
thus the study did not cover the Italian-speaking region.
Data were collected using questionnaires in the local lan-
guages of German and French. The physician interviews
were performed from 10 May to 15 June 2012. Patient data
collection was conducted from 14 May to 07 September
2012.
The study protocol, patient information and questionnaires
were approved by local independent ethics committees. Pa-
tients had to sign an informed consent form before study
entry and study conduct followed Good Clinical Practice
(GCP) guidelines. Confidentiality of the participants was
observed at all times. The IMPROVE study flowchart is
shown in figure 1.
Study participants and questionnaires
Physicians
The key inclusion criteria for physicians were active in-
volvement in OMT and willingness to answer the question-
naire. Physicians’ data were collected through telephone
interviews using a 54-item computer-based questionnaire.
The questions addressed knowledge about and attitudes to-
wards OMT, illicit drug use, guidelines and administrat-
ive requirements, and difficulties in treating patients. Re-
sponses were entered directly into the computer by the in-
terviewer. On average, an interview lasted for 27 minutes.
Patients
A total of 250 opioid-dependent patients on OMT were
planned to be recruited from seven sites in Switzerland,
50% of whom would come from physician’s offices, and
50% from substitution treatment support centres. The ra-
tionale behind this recruitment strategy was based on data
from the methadone case register of canton Zurich, which
indicated that 48.0% of OMTs are managed by general
practitioners (GPs) and 47.6% by specialised treatment
centres [11].
Figure 1
The Swiss IMPROVE study flow chart and disposition of subjects.
OMT = opioid maintenance therapy
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A total of 45 GPs agreed to distribute the patient question-
naires; 31 (69%) sent back completed questionnaires and
14 (31%) did not.
Six physicians from treatment centres in five cantons dis-
tributed questionnaires to OMT patients at their respective
centres.
All recruiting physicians were instructed to recruit patients
in a random manner.
Only opioid-dependent patients currently on OMT who
signed the informed consent form and were willing to an-
swer the questionnaire were included in the study.
A paper-based questionnaire consisting of 83 questions
was used for patient data collection. The questionnaire
covered sociodemographics, previous and current substitu-
tion therapy (type, access, satisfaction, scope for improve-
ment, etc.), illicit drug use, drug diversion and the black
market, and prison experience. The questionnaires were
handed out at physician’s offices and centres and the pa-
tients had to complete (approximately 25–30 minutes)
these on site. Data were collected anonymously, with no
individually identifiable health information included in the
questionnaires and datasets. The completed questionnaires
were to be archived for 1 year and then destroyed.
Statistical analyses
The planned patient sample size (n = 250) was the max-
imum realistic number of patients that could be recruited.
However, only 207 eligible patients could initially be in-
cluded in the study. An additional 10 patients were later ad-
ded to boost the sample size of buprenorphine users to n =
36. In order not to bias the total sample, the boost sample
was not included in the overall analysis, but was used in
specific analyses stratified by medication type.
Physicians’ and patients’ datasets were analysed separately.
Data summaries were provided using descriptive statistics
for continuous variables, and frequency tables (absolute
counts and percentages) for categorical variables. Signific-
ance testing at the 95% and 99% levels was applied where
feasible (n >29). No comparison between the two datasets
was performed.
Where appropriate, analyses took into account the multi-
cultural and multilinguistic character of the population, and
regional and demographic variations were indicated.
Results
Study participants
Physicians’ profile
From a database of OMT physicians, 1,397 were con-
sidered for participation in the study. Of these, 1,165 (83%)
refused participation, 25 (2%) did not meet all inclusion
criteria, and 39 (3%) dropped out during the interview peri-
od (fig. 1).
A total of 200 (14%) physicians (44% GPs, 33% psychiat-
rists and 19% internists) completed the survey, with a mean
age of 54.1 ± 8.2 (range 33‒70) years.
The majority of the respondents were male (87%), and the
largest proportion (79%) worked in a private practice; 16%
worked in an outpatient clinic and 6% in a hospital. More
than half (59%) reported a caseload of ≤9 OMT patients,
Figure 2
Regional distribution of study participants. Dark oval fields
represent the physicians. White rectangular fields represent the
patients. Abbreviations on the map represent the different cantons
of Switzerland. Patients were recruited from Bern (BE), the Basel
area (BS/BL), Fribourg (FR), Vaud (VD) and Zurich (ZH).
Figure 3
The age profile of the interviewed physicians by specialisation,
work setting, linguistic region and detailed regional distribution.
GP = general practitioner; OPC = outpatient clinic
Figure 4
A summary of opioid maintenance therapy medication choices in
Switzerland. A. Patients’ current medication. B. Most frequently
prescribed medications. C. Medications most frequently requested
by patients, as reported by physicians.
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19% treated 10 to 19 patients, and 22% had ≥20 patients.
The demographic characteristics of the interviewed physi-
cians by specialty, work setting and years of experience in
OMT are given in table 1.
The majority of the respondent physicians (68.5%) were
based in the German-speaking part of Switzerland, and
31.5% in the French-speaking regions. The regions of
Espace Mittelland (n = 48), Lake Geneva (n = 44) and
Zurich (n = 38) accounted for the majority of participants.
The regional distribution of the interviewees is shown in
figure 2.
Participating physicians from the French-speaking region
were significantly older than their counterparts in German-
Figure 5
A summary of satisfaction with current medications and opioid
maintenance therapy (OMT). The patients’ satisfaction was further
stratified according to medications used.
Figure 6
A summary of data on misuse, diversion and parallel use. A.
Patient-reported data on the different ways of diversion, and misuse
and the frequency of parallel consumption of illicit drugs. B.
Physician-reported data on views about misuse and diversion and
their reaction to these problems.
speaking Switzerland (56.5 vs 52.9 years; p <0.01). On av-
erage, GPs were significantly older than psychiatrists (56.6
vs 50.1 years; p <0.01); those working in a private prac-
tice were significantly older than hospital-based physicians
(55.6 vs 48.5 years; p <0.01). The age profile of the parti-
cipating physicians is summarised in figure 3.
Patients’ profile
A random sample of 207 patients was included in the study,
87 of whom were recruited from 31 physicians’ practices,
and 120 from six support centres (fig. 1). No data on
screening failures or drop-out rates among OMT patients
were available.
A total of 144 German questionnaires (69.6%) were com-
pleted and 63 (30.4%) were in French. An additional 10 pa-
tients (all German-speaking) were added to boost the sub-
sample of buprenorphine patients, to be used in specific
analyses only.
The canton Zurich and the combined Basel area accounted
for 34% and 20% of patients recruited, respectively. The
geographic distribution of the patient respondents is shown
in figure 2.
The majority of the patients were male (66%) and single
(60%). More than half (51%) were unemployed and >92%
had finished obligatory schooling or attained secondary
and tertiary education
The mean patient age was 39.8 ± 9.3 (range 20‒61) years.
On average, patients rated their physical and mental health
statuses as mediocre, with little variation between regions.
The sociodemographic data of the IMPROVE patients are
summarised in table 1.
Treatment goals
Physicians
Nearly half of the physicians (46%) cited social commit-
ment as the main reason for treating patients with OMT,
and 24% cited therapeutic efficacy. Social stabilisation of
the patient, and reduction of health risks, illegal activities
and criminality were the top three most important goals of
OMT, reported by 9%, 8.8% and 8.6% of respondents, re-
spectively. Stopping all illegal drug use and achieving a
drug-free state were rated as the least important goals.
Patients
The majority of patients (79%) started OMT on their own
decision. Approximately 34% cited their main motivations
for initiating OMT as the desire to improve general health
and 30% wanted to end their drug dependence for good.
Less than a third (29%) considered the high expense of
drug consumption as another important reason for OMT.
Medication choices
Physicians
In terms of medication choices, data on OMT prescription
volume (expressed in % patient load) showed that, on aver-
age, physicians prescribed liquid methadone (oral) to 60%
of their patients. Methadone tablets and capsules accounted
for almost 20% and buprenorphine for over 12% of pre-
scribed volume. Buprenorphine was more likely to be pre-
scribed by psychiatrists and internists (19% and 13% of pa-
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tient load, respectively) than by GPs (6%; p<0.05). It was
also prescribed more often by physicians in hospitals and
outpatient clinics (18% of patient load) than in private prac-
tice (11%; p<0.05).
Liquid methadone was generally the preferred medication
in all regions. Physicians in French-speaking Switzerland
prescribed liquid methadone to more than 78% of their pa-
tients, significantly higher than physicians in the German-
speaking regions (52%; p<0.05). Prescription volume per
region indicated a high preference for liquid methadone in
the Lake Geneva and Espace Mittelland regions (82% and
70% of patient load, respectively). Buprenorphine had a
higher following in the German-speaking (14% of patient
load) than in the French-speaking region (8%; p<0.05), and
accounted for up to 18% of prescription volume in cent-
ral and northwest Switzerland. Table 2 summarises physi-
cian data on prescription volume of different OMT drugs,
broken down by specialisation, work setting and regional
distribution.
The reasons cited by physicians for their preference for
liquid methadone were personal experience (30% of re-
spondents), safety (21%) and recommendations in
guidelines (16%). For methadone tablets and capsules,
compliance (35%), usage (30%) and personal experience
(21%) were the main grounds for preference. Efficacy
(41%), personal experience (41%) and safety (24%) were
the top reasons for preferential prescription of bupren-
orphine by the physicians interviewed.
Physicians were also asked to rate the importance of drug
attributes in influencing their prescription choice. Effect-
iveness in controlling cravings was ranked the most im-
portant attribute (8.4%), closely followed by safety and tol-
erability (8.1%), whereas therapy cost was ranked as the
least important (5.5%).
Overall, 39% of physicians stated that patients always or
often request a specific substitution medication. This fre-
quency was highest among psychiatrists (53%) and among
physicians in outpatient clinics/hospitals (53%), and lowest
among GPs (25%; p<0.05). The medication most often
requested was liquid methadone (49%), with the highest
proportion of requests coming from the Lake Geneva re-
gion (79%). The highest frequency of patient requests for
buprenorphine was reported in Espace Mittelland (22% of
physicians). Of the physicians who received specific re-
quests from their patients, 61% granted the requests ≥70%
of the time.
Patients
Of the 207 patients interviewed, 47% were on liquid meth-
adone, 31% on methadone tablets or capsules, and 13% on
buprenorphine (fig. 4). Other substitution medications used
were morphine retard and codeine. Generally, patients had
a major influence on the choice of medication, with 48%
of patients reporting they were given the option to choose,
and 54% given the drug of their choice.
Detailed data on medication use presented by age, gender,
employment status and geographic region are presented in
table 2. In terms of demographics (including 10 boost pa-
tients), methadone tablets were the preferred OMT medic-
ation among women (p<0.05). A significantly higher pro-
portion of buprenorphine users were employed (47.2%)
compared with methadone liquid and tablet users (28.6%
and 21.5%, respectively; p<0.05).
Excluding boost patients, regional differences were noted
in terms of OMT medication use. Methadone was generally
the drug of choice in all cantons surveyed, with liquid
methadone use significantly higher in Vaud (81% of pa-
tients) and Bern (77%; p <0.01) compared with other can-
tons surveyed.
Satisfaction with medications and therapy
Physicians
Out of the 200 physicians interviewed, 77% were of the
opinion that OMT is easy for patients to access in their geo-
graphic area, whereas 11% considered it difficult. The dif-
ficulty was attributed mainly to imbalance between therapy
supply and demand, as well as the personal problems of the
patients.
On a 10–point satisfaction scale, 83% of physicians were
satisfied (score 7‒10) with the treatment programmes in
their area, and only 2% were dissatisfied (score 1–4). The
satisfaction ratings of physicians are shown in figure 5.
Patients
The majority (85%) of OMT patients were very (46%) or
fairly (39%) satisfied with their current medication. Sat-
isfaction was significantly higher among buprenorphine
(94%) and liquid methadone users (85%) compared with
users of methadone tablets or capsules (80%; p<0.05). In
terms of the overall success of OMT, 88% were very (45%)
and fairly (43%) satisfied. Buprenorphine (97%) and liquid
methadone (91%) users were significantly more satisfied
(p<0.05) with their therapy than users of methadone tablets
or capsules (78%). Patient satisfaction is graphically
presented in figure 5.
Regional differences in therapy satisfaction were not sig-
nificant, with a trend towards lower satisfaction in Zurich
and Fribourg.
Misuse, diversion and parallel use
Physicians
With regards to diversion and misuse, 45% of all physi-
cians interviewed reported that diversion of substances was
a significant or huge problem. This perception was simil-
ar between German- and French-speaking regions, but was
considered most problematic in Eastern Switzerland (63%)
and least in Zurich (29%).
About a third (32%) of all doctors considered medication
misuse (e.g., injecting, snorting) a huge or significant prob-
lem, with a higher problematic rating in the French-speak-
ing region (rated 38% of physicians), especially in the Lake
Geneva area (34%).
As reaction to misuse or diversion, 63% of physicians
would try to find out the reason for the patient’s action and
find a solution; 26% would warn patients of therapy inter-
ruption if misuse or diversion persists. Only 9% would re-
sort to immediate therapy cessation. A summary of misuse
and diversion data is given in figure 6.
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Patients
Of the 207 patients interviewed, 66% admitted to using il-
licit drugs at least one to two times a month; daily use was
reported by 8% of respondents. Parallel use of illicit drugs
was highest among liquid methadone users (71%) and low-
est (53%) among buprenorphine users (p <0.05).
The main reasons for misuse cited were the need to get
high occasionally (41%) and the inability of the current
therapy to control cravings (20%). There was great vari-
ation in availability of medications on the street, with ben-
zodiazepines (69%) and methadone (59%) reported as the
easiest to access. It is important to note that 19% of patients
declined to answer this question.
About a third (37%) of respondents admitted to having di-
verted their prescribed medications, with 13% admitting
to having sold their drugs and 24% to having given theirs
away without financial compensation. Thirty-seven percent
admitted to deviating from the officially prescribed use of
their OMT drug, with 24% admitting to injecting and 13%
to snorting their medications.
Barriers and unmet needs
Physicians
The most frequent reason, cited by 70% of physicians, for
not treating OMT patients was the difficulty in handling
opioid-dependent patients, followed by the current political
conditions (15%).
Approximately 64% of physicians agreed that the necessity
of attending all appointments was the most important, yet
also the most difficult, rule for patients to abide by, thus
presenting a major barrier for OMT participation. In corol-
lary to this, the most commonly reported barriers that led
Table 1. Demographic characteristics of study participants.
Physicians
n = 200
Demographic data Patients
n = 207*
Gender, n (%)
173 (86.5) Male 137 (66.2)
27 (13.5) Female 69 (33.3)
– No response 1 (0.5)
Age (years)
33‒70 Range (min‒max) 20–61
54.06 ± 8.15 Mean ± standard deviation 39.77 ± 9.29
55 Median 41
Age groups, n (%)
– ≤19 years 1 (0.5)
– 20–29 years 33 (15.9)
8 (4.0) 30–39 years 58 (28.0)
50 (25.0) 40–49 years 85 (41.1)
82 (41.0) 50–59 years 25 (12.1)
57 (28.5) 60–69 years
3 (1.5) >70 years
3 (1.4)
– No response 2 (1.0)
Specialisation, n (%) Level of education, [n (%)
General practitioner 87 (43.5) Did not finish school 16 (7.7)
Psychiatrist/psychologist 66 (33.0)
Internist 37 (18.5)
Finished obligatory school only 58 (28.0)
Other 10 (5.0) Apprenticeship 110 (53.1)
Matura 16 (7.7)
University degree 7 (3.4)
Work setting, n (%) Employment status, n (%)
Private practice 144 (72.0) Unemployed 106 (51.2)
Outpatient clinic 32 (16.0) Employed 62 (30.0)
Full time 23 (11.1)
Part time 39 (18.8)
Private practice specialised in addiction medicine 13 (6.5)
Job seeker 34 (16.4)
Hospital 11 (5.5) Student / job training 3 (1.4)
Don’t know 2 (1.0)
Involvement in substitution therapy, n (%)
(Mean 16.3 ± 6.7 years)
Relationship status, n (%)
1–4 years 10 (5.0) Single 125 (60.4)
5–9 years 31 (15.5) Divorced 41 (19.8)
10–14 years 41 (20.5) Living with someone 23 11.1)
15–19 years 37 (18.5) Married 14 (6.8)
20–24 years 41 (20.5) Widowed 3 (1.4)
25–29 years 23 (11.5) No response 1 (0.5)
≥30 years 17 (8.5)
* excluding boost
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to therapy interruption were the inability of patients to ad-
here to the treatment rules (cited by 79% of physicians), pa-
tients changing place of residence (50%) and imprisonment
(29%).
In the physicians’ opinion, changes were needed to motiv-
ate medical practitioners to engage in OMT. The top two
factors that needed to be changed were the lack of training
and/or information (cited by 33%) and the financial bar-
riers in relation to doctors’ compensation (20%). In con-
nection with the information gap, only 83% of physician
respondents were familiar with the clinical guidelines and
joint OMT recommendations of SSAM, VKS and FOPH.
Of those who were aware of these Swiss practice
guidelines, 83% found them useful in their daily practice.
Current political conditions and framework were also con-
sidered by 15% of respondents as a barrier, with changes
desired in terms of less bureaucracy, less complicated ob-
ligations and more support for OMT physicians.
Regarding quality of patient care, the need for change in
the Swiss political framework was cited as most important
by 13% of respondents. Other areas for improvement iden-
tified were increasing access by patients to OMT (reported
by 12%), and enhancing the attractiveness of treating
opioid-dependent patients to physicians (10%).
Patients
The majority of patients (75%) informed themselves of
the different treatment options before initiating OMT and
76% felt they were very well-informed (33%) or well-in-
formed (43%) about OMT. The main sources of informa-
tion were other drug users, reported by 52% of respondents,
followed by counselling or drug support centres (47%),
friends and acquaintances (43%) and the OMT physician
(41%). However, 21% of respondents felt insufficiently or
poorly informed about OMT.
A total of 153 respondents knew of current users who were
not in OMT. The reasons reported for not starting therapy
were the user’s feeling of being able to cope effectively
with the situation (cited by 24%) and not feeling addicted
at all (23%). Other reasons included lack of flexibility in
therapy appointments (22%) and the long duration until a
maintenance dose could be achieved (15%).
Several prerequisites to starting OMT were considered as
difficult to meet, especially daily supervised consumption
(cited by 70% of respondents), the necessity of attending
all appointments (63%) and psychosocial counselling
(41%), the long-term goal of a drug-free state (39%) and
cessation of all illicit drug use (38%).
Discussion
Despite Switzerland’s seemingly progressive approach to
OMT, the system is far from perfect. Treatment barriers and
unmet needs that were identified by the IMPROVE study
included political, financial and social problems discussed
below. These present opportunities for improving the Swiss
OMT model.
The IMPROVE data showed that liquid methadone re-
mained the most common OMT medication preferred by
patients and prescribed by physicians in Switzerland. The
number of buprenorphine users in Switzerland remains
low.
Despite different pharmacological properties, methadone
and buprenorphine are both considered to be effective and
safe medications in OMT and are given equal merit by
the SSAM and the FOPH guidelines [10, 9]. Several clin-
Table 2: Medication choices by demographics and by regions – physician- and patient-reported data
Physician-reported data: volume of prescribed OMT medications expressed in mean percentage (%) of patient load by specialisation, work setting and linguistic and
regional distribution§
Specialisation (%) Work setting (%) Linguistic region (%) Detailed regional distribution (%)Medication
prescribed
Mean %
patient
load
GP
n = 87
Internist
n = 37
Psychiatrist
n = 76
Private
practice
n = 157
OPC/
hospital
n = 43
German-
speaking
CH
n = 137
French-
speaking
CH
n = 63
Eastern
CH
n = 32
Zurich
n = 38
Central
& NW
CH
n = 38
Espace
Mittelland
n = 38
Lake
Geneva
region
n = 44
Liquid
methadone
60.1 64.3 59.0 56.0 62.7* 50.7° 51.8° 78.3** 52.7° 44.1° 44.6° 70.1** 81.9**
Methadone
tablets/
capsules
19.9 23.2 25.9 13.2 19.8 20.2 24.7 9.4 23.6 32.8 29.9 11.0 7.0
Buprenorphine 12.2 5.9° 12.8* 19.0** 10.6 18.0* 14.3* 7.5 14.5 11.2 17.9 13.2 5.2
Patient-reported data: OMT medication by demographics and regional distribution§
Age groups, with boost (%) Gender, with boost
(%)
Employment, with
boost (%)
Detailed regional distribution (%), excluding boostMedication
prescribed
Total
n = 207
(+10
boost)
≤29
years
30‒39
years
≥40 years Female Male Employed Unemployed
+ other
BS/BL
n = 41
BE
n = 35
ZH
n = 71
FR
n = 29
VD
n = 31
Liquid
methadone
98 18.4 25.5 55.1 27.6° 72.4 28.6° 71.4 39° 77** 37° 14° 81**
Methadone
tablets/
capsules
65 12.3 32.3 55.4 43.1* 56.9 21.5° 78.5 41 0.0 35 52 26
Buprenorphine 26 (+10) 27.8 25 47.2 30.6° 69.4 47.2* 52.8 7 17 10 34 0.0
*/** Values were tested and found to be significantly different at (**) p <0.01 and (*) p <0.05 compared with number(s) marked ° in the same category.
§ Percentages may not add up to 100% owing to data on other medications not reported in the table. “Others” included, but were not limited to, morphine, diamorphine,
codeine and prescribed heroin.
Boost: 10 patients who were buprenorphine users added to boost the sample size to n = 36. Regional distribution excluded boost patients as these only consisted of
participants from German-speaking CH.
BE = Bern; BS/BL = Basel area; CH = Switzerland; FR = Fribourg; GP = general practitioner; NW = northwest; OPC = outpatient clinic; VD = Vaud; ZH = Zurich
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ical trials and systematic reviews have compared the two
medications [12–15]. Advantages associated with methad-
one are higher retention rates, and better patient control
and dosage adaptation. Buprenorphine, on the other hand,
has the safety advantage of being less proarrhythmic than
methadone and allowing faster achievement of steady-state
dose without the risk of serious overdose with respiratory
depression. In addition, dispensing in intervals of 2 to 3
days is possible for the latter [10], supporting the practice
of allowing take-home medications. A main disadvantage
of buprenorphine is its higher cost in comparison with
methadone.
Some European countries have reported potential shortages
in OMT healthcare providers as ageing physicians retire
and are not replaced by younger doctors [16, 17]. This
trend was reflected in the IMPROVE data, with 31% of
physician respondents being 60 years and above. Particip-
ating GPs and internists were generally older than psy-
chiatrists, and a similar trend in age difference was also
evident between practice-based and clinic/hospital-based
physicians. The ageing GPs and the practice-based physi-
cians represented a considerable bulk of the IMPROVE re-
spondents and could well correspond to the real-life demo-
graphics of Swiss OMT providers. Even though the number
of OMT patients in Switzerland is not necessarily increas-
ing [9, 10], the IMPROVE data on OMT physician demo-
graphics indicate a potential imbalance in OMT supply and
demand that needs to be addressed before a bottleneck is
reached.
Patients’ satisfaction with their treatments is not often ana-
lysed. The IMPROVE data showed that, in general, sat-
isfaction with OMT therapy and medications in Switzer-
land was high. However, although substantial improve-
ments have been made since the open drug scenes in the
1980s, a number of opioid-dependent individuals have not
been integrated into OMT. In addition, OMT still generally
follows a revolving door pattern of initiation and dropping
out. Certain clinical practices were found by IMPROVE
patients to be too restrictive and presented as barriers to
therapy entry and retention.
Physicians were also generally satisfied with the availab-
ility of OMT in their area. However, several factors were
identified by the medical professionals as areas for im-
provement. Based on the respondent physicians’ views, the
Swiss political framework, the accompanying bureaucracy,
as well as financial issues were identified as barriers that
deter physicians from providing OMT. Lack of information
and training and the negative perception of OMT patients
as being difficult were also cited as hindrances.
In general, high satisfaction with OMT in the Swiss setting
was consistent for both OMT patients and treating physi-
cians, although this was not statistically tested.
As an indication of abovementioned information gap, a
significant proportion of the treating physicians (17%, un-
published data IMPROVE) were not aware of the current
SSAM/VKS/FOPH clinical guidelines on OMT [10], in-
cluding the existence of effective treatments other than
methadone, and the importance of diversification of OMT
to optimise and individualise therapy to the needs of the
patients. Recently, morphine retard was also approved by
Swissmedic for the indication of OMT, providing another
treatment option.
The abovementioned shortcomings and other barriers iden-
tified by the IMPROVE study need to be addressed in order
to increase the willingness of physicians to engage in OMT
(and thus address the supply and demand imbalance pre-
viously mentioned), optimise treatment outcomes, and im-
prove further the Swiss OMT model.
Unsupervised and take-home doses of substitution med-
ications on weekends and holidays is common practice
in Switzerland (unpublished data, IMPROVE) but could
present an opportunity for misuse and diversion of OMT
medications. Indeed, many OMT patients admitted to
snorting or injecting their medications, or giving them
away. However, the main motivation for diversion was
not necessarily financial gain but rather sharing with other
users, indicating minimal involvement of patients in selling
prescribed OMT in the black market.
Many physicians were concerned about misuse and di-
version although surprisingly many of the IMPROVE re-
spondents did not consider either as a huge problem in their
geographic area. As response to the problems, the majority
of physicians took a proactive approach, in keeping with
the Swiss harm reduction drug policy, by trying to find out
reasons for misuse and possible solutions; only very few
took the hardline position of immediate OMT interruption.
There were some limitations in the IMPROVE study. The
canton of Tessin, which comprise the Italian-speaking part
of Switzerland, could not be included in the study because
of resource and logistical constraints. However, the largest
Italian-speaking city of Lugano ranks only 9th in Switzer-
land in terms of population size. The number of Italian-
speaking participants would have been small and did not
justify the additional costs of documentation (e.g., transla-
tion of questionnaires and other study documents) and lo-
gistics.
Although physicians were instructed to randomly select
participating patients, this could not be fully ensured and
documented. In addition, only a small number of bupren-
orphine users could participate in the study, which could
have been a source for bias. However, appropriate meas-
ures during the analysis were taken to avoid this.
Limitations related to questionnaire-based research also
need to be considered. The questionnaires used in this
study were not validated instruments, but modelled on
those used in previous studies, in order to facilitate com-
parison, as discussed below.
Finally, limitations inherent to observational cross-section-
al studies should be kept in mind when interpreting the res-
ults of the IMPROVE study. The representativeness of the
IMPROVE populations and their generalisability to other
populations could not be confirmed. Owing to the uncon-
trolled study design, data and comparisons could only be
interpreted in a descriptive manner.
Switzerland is not alone in addressing present-day OMT
problems. The pan-European project European Quality
Audit of Opioid Treatment (EQUATOR) is assessing the
current state of opioid-dependence treatment in ten coun-
tries across Europe [18]. The questionnaires used in the
IMPROVE study were similar but not identical to those
used in the EQUATOR study. This is a result of several
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differences between the Swiss OMT landscape and other
European countries. EQUATOR surveyed both OMT pa-
tients and out-of-treatment users, whereas IMPROVE only
included OMT patients. With the majority of Swiss users
in treatment [9], it was not feasible for IMPROVE to enrol
enough opioid users not in treatment. Despite these differ-
ences, the research design of IMPROVE was comparable
enough to that of the EQUATOR survey to allow compar-
ison with data from other countries in future publications.
Conclusions
The subset of IMPROVE data presented here gives a
present-day, real-life overview of the OMT landscape in
Switzerland which has not been previously assessed and
published in any scientific journal. It gives a glimpse into
the profile of the present-day OMT Swiss patients as well
as those of the current OMT healthcare providers. It also
addressed many knowledge gaps in the field of addiction
medicine, including treatment satisfaction, unmet needs,
the prevalence of misuse and diversion and the common
barriers to therapy.
The dataset represents a valuable resource for policy
makers, key opinion leaders and drug addiction researchers
and will be a useful basis for improving the current Swiss
OMT model. Further publications on other important as-
pects of the IMPROVE study is planned.
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Figures (large format)
Figure 1
The Swiss IMPROVE study flow chart and disposition of subjects.
OMT = opioid maintenance therapy
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Figure 2
Regional distribution of study participants. Dark oval fields represent the physicians. White rectangular fields represent the patients.
Abbreviations on the map represent the different cantons of Switzerland. Patients were recruited from Bern (BE), the Basel area (BS/BL),
Fribourg (FR), Vaud (VD) and Zurich (ZH).
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Figure 3
The age profile of the interviewed physicians by specialisation, work setting, linguistic region and detailed regional distribution.
GP = general practitioner; OPC = outpatient clinic
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Figure 4
A summary of opioid maintenance therapy medication choices in Switzerland. A. Patients’ current medication. B. Most frequently prescribed
medications. C. Medications most frequently requested by patients, as reported by physicians.
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Figure 5
A summary of satisfaction with current medications and opioid maintenance therapy (OMT). The patients’ satisfaction was further stratified
according to medications used.
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Figure 6
A summary of data on misuse, diversion and parallel use. A. Patient-reported data on the different ways of diversion, and misuse and the
frequency of parallel consumption of illicit drugs. B. Physician-reported data on views about misuse and diversion and their reaction to these
problems.
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